Canori et al. (2026)
- Authors: Alexandra Canori, Eric Watson, Devanshi Patel, Arianna Fiorentino, Christopher Santiago, David Maltz, Blake Gurfein, David Putrino, Jacqueline Becker
- Institutes: Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY, Fareon, Inc, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
- Publisher: medRxiv
- Link: DOI
Summary
This research introduces a novel, passive treatment for one of the most disabling symptoms of Long COVID. By providing a safe and effective at-home option for cognitive rehabilitation, Microtesla Magnetic Therapy (MMT) could significantly improve the quality of life for millions of individuals suffering from persistent “brain fog” and related mood disturbances. The study’s results offer a promising non-pharmacological pathway for managing neuroinflammatory conditions.
What was researched?
The study evaluated the feasibility, safety, and preliminary efficacy of at-home Microtesla Magnetic Therapy (MMT) for treating cognitive impairment in patients with Long COVID.
Why was it researched?
Cognitive dysfunction in Long COVID is linked to persistent neuroinflammation and mitochondrial impairment, which MMT is hypothesized to mitigate through low-amplitude magnetic fields.
How was it researched?
This triple-blind, randomized controlled trial enrolled 30 participants who were assigned to receive either active or sham MMT. Participants self-administered 15-minute sessions twice weekly for four weeks using a head-worn device with remote supervision. Outcomes were assessed at baseline, four weeks, and eight weeks using a standardized neurocognitive battery and self-report measures.
What has been found?
The intervention demonstrated 100% adherence and an excellent safety profile with no device-related adverse events. Significant improvements were observed in the active group for working memory, verbal learning, and executive functioning at the 8-week follow-up. Additionally, participants receiving active treatment reported significant reductions in fatigue and improved emotional well-being compared to the sham group.
Discussion
The study’s small sample size and exploratory nature mean that the results should be interpreted with caution. However, the durability of the cognitive gains at the follow-up visit suggests that the therapy may promote gradual resolution of underlying neuroinflammation rather than just temporary effects.
Conclusion & Future Work
At-home MMT is a feasible and safe non-pharmacological intervention for Long COVID brain fog. Larger clinical trials are warranted to confirm these preliminary findings and further clarify the biological mechanisms of action.